{"id":227229,"date":"2025-12-16T17:10:44","date_gmt":"2025-12-16T23:10:44","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/12\/cutaneous-melanoma-a-review"},"modified":"2025-12-16T17:10:44","modified_gmt":"2025-12-16T23:10:44","slug":"cutaneous-melanoma-a-review","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/12\/cutaneous-melanoma-a-review","title":{"rendered":"Cutaneous Melanoma: A Review"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/cutaneous-melanoma-a-review2.jpg\"><\/a><\/p>\n<p>The incidence and prevalence of cutaneous <i>melanoma<\/i> in the US and worldwide have increased over the last 5 decades.<\/p>\n<p>Cutaneous <i>melanoma<\/i> presents as a new, changing, or irregularly pigmented skin lesion. Risk factors for cutaneous <i>melanoma<\/i> include UV radiation exposure, skin type, presence of benign and atypical nevi, and personal or family history of melanoma.<\/p>\n<p>This Review summarizes current evidence regarding the epidemiology, pathophysiology, diagnosis, and treatment of cutaneous melanoma.<\/p>\n<hr>\n<p>Improvements in <i>melanoma<\/i> mortality over the last decade are attributed to the advent of multiple effective therapies,<sup><a href=\"https:\/\/ja.ma\/4qgYh9g#jrv250025r6\">6<\/a><\/sup> including immune checkpoint blockade with anti\u2013cytotoxic T-lymphocyte\u2013associated protein 4 (CTLA-4) antibodies (ipilimumab), anti\u2013programmed cell death protein 1 (PD-1) antibodies (nivolumab, pembrolizumab), and anti\u2013lymphocyte activation gene 3 protein (LAG-3) antibodies (relatlimab), as well as oral combination targeted therapy with B-Raf protein (BRAF) and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors (eg, encorafenib + binimetinib, vemurafenib + cobimetinib, dabrafenib + trametinib).<\/p>\n<p>This review summarizes current evidence regarding epidemiology and risk factors, clinical presentation, diagnosis, and management of cutaneous <i>melanoma<\/i> (<a href=\"https:\/\/ja.ma\/4qgYh9g#jrv250025b1\">Box<\/a>).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The incidence and prevalence of cutaneous melanoma in the US and worldwide have increased over the last 5 decades. Cutaneous melanoma presents as a new, changing, or irregularly pigmented skin lesion. Risk factors for cutaneous melanoma include UV radiation exposure, skin type, presence of benign and atypical nevi, and personal or family history of melanoma. [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,269],"tags":[],"class_list":["post-227229","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-life-extension"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/227229","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=227229"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/227229\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=227229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=227229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=227229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}